Encore Global Management LP acquired a new stake in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the 1st quarter, Holdings Channel reports. The institutional investor acquired 10,800 shares of the exchange traded fund’s stock, valued at approximately $1,379,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Financial Life Planners purchased a new stake in shares of SPDR S&P Biotech ETF in the first quarter worth about $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $27,000. Intesa Sanpaolo Wealth Management acquired a new position in SPDR S&P Biotech ETF during the 4th quarter worth approximately $30,000. SHP Wealth Management acquired a new position in SPDR S&P Biotech ETF during the 4th quarter worth approximately $31,000. Finally, Legacy Wealth Managment LLC ID purchased a new position in SPDR S&P Biotech ETF in the 4th quarter worth approximately $32,000.
SPDR S&P Biotech ETF Stock Down 0.5%
Shares of NYSEARCA:XBI opened at $149.78 on Wednesday. SPDR S&P Biotech ETF has a 52-week low of $84.39 and a 52-week high of $165.71. The company has a 50 day moving average of $145.16 and a two-hundred day moving average of $133.90. The company has a market capitalization of $10.09 billion, a price-to-earnings ratio of 11.47 and a beta of 0.82.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
